Eli Lilly (LLY) Accumulated Expenses (2009 - 2026)

Eli Lilly (LLY) has 18 years of Accumulated Expenses data on file, last reported at $1.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 22.0% year-over-year to $1.4 billion; the trailing twelve-month figure through Mar 2026 stood at $1.4 billion (up 22.0% YoY), and the FY2025 full-year result was $2.4 billion, up 13.42% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $1.4 billion, down from $2.4 billion in the prior quarter.
• Across five years, Accumulated Expenses topped out at $2.4 billion in Q4 2025 and bottomed at $693.1 million in Q1 2022.
• The 5-year median for Accumulated Expenses is $1.2 billion (2024), against an average of $1.3 billion.
• Peak annual rise in Accumulated Expenses reached 55.73% in 2023, while the deepest fall reached 3.82% in 2023.
• A 5-year view of Accumulated Expenses shows it stood at $1.1 billion in 2022, then soared by 55.73% to $1.7 billion in 2023, then increased by 26.88% to $2.1 billion in 2024, then grew by 13.42% to $2.4 billion in 2025, then slumped by 42.78% to $1.4 billion in 2026.
• The last three Accumulated Expenses figures came in at $1.4 billion (Q1 2026), $2.4 billion (Q4 2025), and $2.0 billion (Q3 2025), per Business Quant data.

Peer Comparison